Drug intelligence / Profile preview

cemdomespib

Development stage: Phase 1
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

RTA 901 (cemdomespib) is a small molecule drug under investigation for the treatment of diabetic peripheral neuropathic pain. It acts as an inhibitor of heat shock protein 90 (HSP90), targeting underlying mechanisms of nerve damage and pain in diabetic neuropathy rather than just symptom relief. The drug is being developed by Reata Pharmaceuticals, now a wholly owned subsidiary of Biogen[1][2][4].

Other names: Cemdomespib

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)

Beyond the preview

Go deeper on cemdomespib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cemdomespib.

Explore the full profile